Ekf Diagnostics Holding PLC’s (EKF) “Buy” Rating Reaffirmed at Panmure Gordon
Panmure Gordon reiterated their buy rating on shares of Ekf Diagnostics Holding PLC (LON:EKF) in a research report sent to investors on Friday morning. The brokerage currently has a GBX 17.50 ($0.22) price target on the stock.
A number of other equities research analysts have also recently issued reports on the stock. N+1 Singer upped their price target on shares of Ekf Diagnostics Holding PLC from GBX 18 ($0.22) to GBX 19 ($0.24) and gave the company a buy rating in a report on Monday, September 12th. FinnCap restated an under review rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.
Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.25 on Friday. The company’s market capitalization is GBX 73.96 million. Ekf Diagnostics Holding PLC has a 12-month low of GBX 7.00 and a 12-month high of GBX 23.45. The stock’s 50 day moving average price is GBX 15.14 and its 200 day moving average price is GBX 13.36.
In related news, insider Mills,Christopher H. B bought 9,000,000 shares of Ekf Diagnostics Holding PLC stock in a transaction that occurred on Friday, July 15th. The stock was acquired at an average price of GBX 15 ($0.19) per share, for a total transaction of £1,350,000 ($1,670,792.08).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.